Hello and good evening. I am writing to you as a long

New Post Public Reply Private Reply Replies (1) Message Board
avboy

Hello and good evening. I am writing to you as a long term investor in CEN-Biotech (ticker FITX), and in full support of the company. I would like to give some historical background and investor perspective. I would sincerely appreciate if you would spend the time to read it, and pass it on to the investigation team.

I initially invested in this company in April 2011 when they announced they would be entering the sports nutrition supplement industry (an interest of mine). Creative Edge Nutrition initially reverse merged into a defunct company (ticker LBGE) in 2011 in order to be able to expedite the process of becoming public and bring products to market. The initial CEO of Creative Edge Nutrition (Paul Thomas) announced a product they were going to formulate called Metabolic Xtreme. It was more of a concept and he was slow in moving it forward, and never actually did.

Creative Edge Nutrition subsequently brought in Bill Chaaban to replace him in April 2012 as the new CEO. Shortly after becoming CEO, Bill Chaaban announced milestones and goals over the next couple years in terms of bringing these sports nutrition products to market. He was starting from scratch. However, not only did he bring Metabolic Xtreme to market, but he quickly brought several other products through research and development and to market, including AminoPlex and HyperInfusion. I still use the AminoPlex nutritional products almost daily, and they are great.

Mr. Chaaban also wanted to get a ticker change to reflect the current business that had nothing to do with the old business, so he had it changed from LBGE to FITX. Not only did he get the nutritional side of the company up and running strongly (which is still ongoing), he announced and began development of the medical marijuana subsidiary (CEN-Biotech) in 3/2013. Given the goals announced for the nutritional side, all of which were followed through on over the next couple years, I knew that Mr. Chaaban had integrity and was goal-driven. So, I knew he would work diligently no differently with the CEN-Biotech subsidiary, which he did from the beginning and has continued to do.

Similarly to how he announced goals and plans for the nutritional side of the company, and followed through on every one of them, he also announced goals and plans for the newly formed subsidiary CEN-Biotech. As investors, we again began to see steady progress from the build out of the facility (following full approvals from the Town of Lakeshore, as well as receiving a Ready to Build letter from Health Canada), industry networking, and other tangible progress, everything continued to appear on track. Bill Chaaban recruited an absolutely amazing board of directors (BOD) and medical team consisting of expert physician-scientists with world-renowned recognition in the medical, scientific, research, and financial industries including a prior senior level executive at Fidelity and JPMorgan (see highlighted links below), as well as John Germinario, who works with the US SEC (securities exchange commission). The magnitude and achievements of this personnel would not be joining just any company if the company was not legitimate.

Everything continued to be on track and correlated accurately with every announcement made. Then, we began to run into delays which were due to Health Canada taking much longer than expected for coming to inspect our facility. These delays were months and months despite the company being ready for inspection. When they finally did come to inspect many months later, the report stated that approval was recommended pending the correction of 2 minor issues (a screen over a vent, and the security camera angle). Again, we began to wait many more months for final approval, even though these minor issues were quickly fixed.

In these months of delay, the Town of Lakeshore began to change their stance. They initially welcomed the company to Lakeshore in a public video http://vimeo.com/83685127

and had received approvals for their facility build-out. However, in more recent months while the delays due to Health Canada were occurring, they also decided to try to change the local bylaws and change the zoning in a way which would inhibit CEN-Biotech from operating. A few nearby residents began to complain about the project with outlandish claims/concerns just as license was coming, despite watching the buildings go up and saying nothing for all of the preceding months. It later came out in a letter by the company to the town councilors that the few neighbors were attempting to extort significant compensation in monetary value and employment in return for their support of the company/building, which the company did not stand for (and rightfully so).

These few neighbors were able to influence their local councilors to attempt to write a new bylaw stating medical cannabis grow-ops need to be zoned industrial, not agricultural (CEN-Bio is agricultural). The mayor also began to flip-flop regarding CEN-Bio, suspected to be politically driven. There have been identical zoning motions passed by other towns that were struck down by the provincial government, saying that grow-ops do not require industrial zoning. The town clearly knew what was being built the whole time, provided building permits, along with the ready to build letter from Health Canada. There was a letter written from these few residents and their attorney to Health Canada as well asking them to delay/avoid license to CEN-Biotech, which added more delay.

Along with the delay from the above issues, we began to see an assault against CEN-Biotech by the media. In particular, Grant Robertson of the Globe and Mail has targeted CEN-Biotech with continuous assault of articles, many of which have not been based on true facts, and twisting of the actual facts. I have watched his articles timed with every time that the stock has a continued uptrend. He will release several articles in a row which causes the stock to drop significantly. I have watched this occur over and over. I honestly feel that he has an agenda against the company, whether it is being funded by trader groups, or competition, or something else. I sincerely hope that he is investigated in this as well, because he is a central piece. Matt Finston and Chris Parry are two bloggers who have also been relentlessly attacking CEN-Biotech during all of the delays they have suffered, driving share price further down. In fact, Grant Roberston has quoted and discussed Matt Finston several times in his articles, and I wouldn't be surprised if these individuals were all working together somehow. I truly hope this investigation is fair and they are all investigated. Matt Finston has also talked about shorting FITX on his Twitter and there are shareholders who have all of these screenshots saved.

There is documentation of Libby Davies meeting with the Tilray lobbyists, and later on Libby was quoted in one of Grant Robertson's bash articles on CEN-Biotech, also attacking the company. I hope that paper and money trails are evaluated with these individuals. The prior CEO of Tweed was also bashing FITX on his Twitter. I feel there is an orchestrated attach against the company, likely from competitors who feel threatened by CEN-Biotech since they would be the largest grower upon licensure, and possibly from trading groups who could be shorting the stock. This is just speculation, but I wouldn't at all be surprised as I have watched everything closely unfold since the beginning. These misleading articles, blogs, and events have influenced Health Canada negatively, which led to license denial for CEN-Biotech.

Please read through this page on the CEN-Biotech website, which addresses many of these issues and investor concerns:
http://www.cenbiotechinc.com/PlatformApps/CEN/c1/faq.html


Never once did I feel misled in anyway by any announcements or public releases. There are over 2100 investors on a dedicated CEN-Biotech investor page on the internet alone who feel the same way, which is why we have stuck it out continuously. We have lost significant value in our investments. This is not because of Bill Chaaban, any statements he has made, or any announcements by the company. These losses are purely due to the events, agendas, and manipulation discussed above, which have erroneously influenced Health Canada. CEN-Biotech has been painted in a very unfair light in the media. As one of many investors, I'm sick of watching it happen with no repercussions against these individuals (such as Grant Robertson, Mayor Tom Bain and councillors, local neighbors in Lakeshore, Matt Finston, and Chris Parry). The only investigation that should be ongoing in my opinion is against Grant Robertson, these aforementioned individuals, the Town of Lakeshore, and Health Canada, rather than the company itself. I sincerely hope that your team will quickly find this to be the case.

For those with disabling neurologic diseases (I changed this line slightly for privacy reasons), it is an absolute shame how much of a delay the company has sustained in beginning their research and development of medical cannabis strains and medications, all due to the influence from misleading articles and manipulative behaviors above, as well as unjust retroactive changes in bylaws that the town of Lakeshore has been attempting to pass. I continued to stay invested in CEN-Biotech because I was excited (and still am) with their plans for moving the science of medical cannabis forward, along with the outstanding medical professionals they had collected on their Board of Directors who would be involved in the research and company. It is honestly quite sad for the patients who need better quality medications, which CEN-Biotech has been waiting to begin production of, only to continue being delayed for unjust reasons as discussed above.

I implore you to please investigate fairly, and please investigate the entities mentioned above who have played the biggest role in loss of shareholder value. I have watched this company unfold from the beginning. I have watched Bill Chaaban attain the company's stated goals until the above issues halted the company's progress. I only hope that these issues will be brought to light and the company is cleared and able to continue with their previously stated goals for the future.

Sincerely,
XXX






.



Unlike · Comment
.






You and 53 others like this.
.








View previous comments
..










Michael Peterman Is there a cliff notes version lol.

Yesterday at 12:51pm · Like · 1

Creative Edge Nutrition Inc. (FITX) Stock Research Links

FITX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Better Home & Finance Tumbles: Legal Woes and Losses Mount

Updated Category News Views 0

Better Home & Finance's Financial Freefall The rollercoaster of stock markets sees plenty of ups and downs, but when you tack on a securities class action, it’s more like getting stuck on a loop. That’s exactly where Better Home & Finance (NASDAQ: BETR) finds itself after the wheels came off in their Q1 2026 report. A gut-wrenching 75% jump in their net loss tells you...

Continue Reading
Cytrellis Boosts Aesthetics Training With Miami Partnership

Updated Category News Views 22

Cytrellis Partners with University of Miami The announcement from Cytrellis Biosystems is drawing some attention. The company's jumped into a new partnership with the University of Miami School of Nursing and Health Studies, looking to jazz up their Aesthetic Medicine Certificate Program. The kicker here is the introduction of Cytrellis' ellacor® system, a fancy bit of...

Continue Reading
Skechers Faces Shareholder Lawsuit: Must Act by Dec 21

Updated Category News Views 69

Skechers Shareholders Stirring Over Lawsuit A fresh wave of legal antics is crashing at the shores of Skechers U.S.A., Inc. (NYSE: SKX) as frustrated shareholders mobilize against the footwear juggernaut. We're talking about a class action lawsuit here, folks, aimed at shaking down some clarity—or maybe just some cold, hard cash—from this bruiser over some sketchy...

Continue Reading
CapCut's AI Growth Combines Video, Image, and Music Tools

Updated Category News Views 114

CapCut's Recognition in the Creative AI Space The shift towards comprehensive creative platforms is taking the tech world by storm, and CapCut's latest nod from Software Experts is turning heads in 2026 with its ambitious integration. Touted for its versatility, CapCut serves creative projects that need an amalgamation of video, image, and audio elements. Tackling the...

Continue Reading
Cerebras Faces Durability Allegations: Investor Alert

Updated Category News Views 57

Cracks in Cerebras' Processor Promises? When you dance with high-stakes tech stocks, sometimes you end up stepping on a few toes. This seems to ring true as Cerebras Systems (CBRS) dances its way into hot water. Allegations from Culper Research suggest their fancy AI processors, which are supposed to be the poster children of reliability, might bow out early. Digging...

Continue Reading
Orbis International to Boost Global Eye Health Efforts

Updated Category News Views 0

Pledge for Vision In a world where a staggering number of folks wrestle with avoidable vision issues, Orbis International is stepping up to the plate with ambitions that feel as bold as they are necessary. Orbis is pouring a significant $32 million into its mission to beef up eye health systems, train a small army of professionals, and apply AI in eye care. Their big bet...

Continue Reading
Phrontline's TJ101 Gains Momentum in Cancer Clinical Trials

Updated Category News Views 119

Encouraging Signs from Phrontline's TJ101 ADC Trials In the high-stakes race to outsmart cancer, Phrontline Biopharma is banking on TJ101, their star investigational bispecific antibody-drug conjugate (ADC). The recent results shared at the ESMO Congress 2026 are stirring up quite a bit of chatter. Urothelial Carcinoma and Beyond Now, picture this: six of eight evaluable...

Continue Reading
Green Methanol: A $20.11B Market by 2032 Excites

Updated Category News Views 9

The Green Methanol Boom Folks, the money's about to get greener—greener methanol, that is. We’re talking about a market that’s set to explode from a humble $3.46 billion in 2026 to a jaw-dropping $20.11 billion by 2032. With a hefty CAGR of 34.1%, it seems like investors might want to buckle up for a bullish ride in this eco-friendly venture. Why Green Methanol?...

Continue Reading
Epicurean Expeditions Mix Food Joy with Ocean Luxury

Updated Category News Views 50

Atlas Expands Culinary Cruise Horizons in 2027 Now here's a twist for you—cuisine meets cruise in a hefty blend of sail, chew, and swirl. Atlas Ocean Voyages is practically throwing a gourmet party on water with their 2027 Epicurean Expeditions. They're unfurling the sails alongside chef heavyweights like Crista Luedtke and wine maestro Anthony Giglio. Imagine a cruise...

Continue Reading
Gate's Strong Q3: Sales Growth & Rising Margins

Updated Category News Views 39

Solid Performance Boosts Confidence Gates Industrial came out swinging with their third-quarter results for 2026, showing some financial prowess that would make even the skeptics raise an eyebrow. Net sales climbed to a hefty $903.6 million, advancing 5.6% from the same time last year. It's not just smoke—core sales jumped 5.5%, signaling they're doing a bit more than...

Continue Reading

Top 5 Most Recently Viewed Articles

Are PEPE, WIF, and POPCAT Set to Eclipse Shiba Inu in 2024?

Updated Category News Views 94

Meme Coins on the Rise: Will PEPE, WIF, and POPCAT Lead the Charge? Several analysts are suggesting that the emerging meme coins PEPE, WIF, and POPCAT could be primed for exceptional growth and outperformance against well-known competitors like Shiba Inu and Dogecoin. With mounting excitement surrounding these digital assets, traders are closely analyzing price movements...

Continue Reading
AppLovin's E-commerce Growth Signals Potential Q4 Upside

Updated Category News Views 226

AppLovin's Recent Momentum in E-Commerce AppLovin Corp (NASDAQ: APP) is experiencing notable momentum as it expands its e-commerce capabilities. This growth is primarily attributed to a significant increase in the number of merchants adopting its Axon advertising technology, which has raised expectations for a potential upside in the fourth quarter. Recent analysis...

Continue Reading
Exploring the Surge in Functional Gummies Market Growth

Updated Category News Views 252

Exploring the Rise of the Functional Gummies Market The functional gummies market is set to witness significant growth as it responds to evolving consumer demands for health-focused products. This market capitalizes on the intersection of nutrition, wellness, and enjoyment, providing essential nutrients in a format that appeals to a wide audience. The transition towards...

Continue Reading
Cavvy Energy Exceeds Expectations with Robust Q3 Results

Updated Category News Views 168

Cavvy Energy Reports Strong Q3 2025 Financial Performance CALGARY, Alberta — Cavvy Energy Ltd. (TSX: CVVY) has released its financial and operational results for the third quarter of 2025, showcasing impressive growth and resilience amidst market challenges. In this quarter, the company reported a production rate of 23,956 barrels of oil equivalent per day (boe/d) and a...

Continue Reading
AI Privacy Risks When Sharing Financial Documents

Updated Category Personal Finance Views 248

AI tools have made life easier in so many ways that one sometimes overlooks their risks. For financial analysis and guidance, an empathetic and supportive AI chatbot may feel like the perfect ally. But that illusion can be damaged if you find business or personal finance information exposed or misused. If you currently use AI tools for financial analysis or assessments,...

Continue Reading